Triple Agonist Ambitions
19:09–20:10 · 61s
Duust teases UBT251, a potential best-in-class drug he hopes will outdo Lilly’s 28% weight-loss candidate.
19:09–20:10 · 61s
Duust teases UBT251, a potential best-in-class drug he hopes will outdo Lilly’s 28% weight-loss candidate.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.